Symbiotec Pharmalab Day 1: GMP ₹388 (39.27%) & 0.85x Subscribed

Key takeaways

• The Symbiotec Pharmalab IPO is looking to raise ₹1,757.00 crore through a combination of a fresh issue (₹150.00 crore) and an OFS (₹1,607.00 crore).
• The price band is fixed at ₹938 to ₹988 per share, and retail investors will need a minimum of ₹14,820.
• On Day 1, the issue witnessed a measured early response, getting subscribed 0.85 times.
• The current Grey Market Premium (GMP) is ₹388, which means the listing gain could be approximately 39.27%.
• The company's financials for FY26 were strong, with a total income of ₹872.26 crore and profit after tax (PAT) of ₹109.90 crore.

Symbiotec Pharmalab Ltd. today launched its much-awaited Initial Public Offering (IPO). It is a leading global manufacturer of corticosteroid and steroid hormone active pharmaceutical ingredients (APIs). Its public issue has attracted the attention of healthcare-focused investors and institutional giants. The IPO is a book-built issue of ₹1,757.00 crores. This includes a fresh issue of 0.15 crore shares valued at ₹150.00 crores and an offer for sale (OFS) of 1.63 crore shares worth ₹1,607.00 crores.

The funds raised through the fresh issue are planned to be utilised for strategic growth, primarily through prepayment and repayment of some outstanding borrowings of ₹112.50 crores, and for general corporate purposes. The total IPO subscription on Day 1 stood at 0.85 times, and the grey market premium (GMP) was at ₹388 at the end of Day 1 bidding. Now, let's discuss Day 1 of the Symbiotec Pharmalab IPO in detail.

Symbiotec Pharmalab IPO key dates

Symbiotec Pharmalab IPO opens for subscription today (August 24, 2026) and will remain open till August 27 2026. The IPO allotment will be finalised on August 28, 2026. The refunds and shares will be credited to applicant accounts by August 31, 2026. The shares are tentatively going to list on the Bombay Stock Exchange (BSE) and the National Stock Exchange (NSE) on September 1, 2026.

JM Financial Limited is the book-running lead manager for this IPO offering, while MUFG Intime India Pvt. Ltd. is the registrar of the issue.

About Symbiotec Pharmalab

Symbiotec Pharmalab is a leading pharmaceutical and biotechnology company in India engaged in the development and production of APIs, biotechnology products and complex injectables. The company operates across three platforms: organic chemistry, biotechnology, and complex injectables.

Symbiotec Pharmalab has a massive portfolio which includes more than 60 corticosteroid and steroid hormone APIs. It has a robust global presence with a 38.2% global volume market share in corticosteroid APIs and 23.8% in steroidal-hormone APIs as of FY26. The company has two API manufacturing plants at Rau and Pithampur in Madhya Pradesh, a newly commissioned biomanufacturing plant at Ujjain and a complex injectables plant at Mhow.

Symbiotec Pharmalab has experienced steady and strong financial expansion. Its total income increased 15% to ₹872.26 crore in FY26 from ₹755.98 crore in FY25. Profit after tax (PAT) also continued to grow steadily, from ₹96.79 crore in FY25 to ₹109.90 crore in FY26.

Day 1 subscription status

At the end of the first day of the bidding, the Symbiotec Pharmalab IPO saw a steady but measured early response as investors weighed its strong market share against its pricing. The issue had 0.85 times total subscription on Day 1.

Non-Institutional Investors (NIIs) subscribed 1.10 times, and the Retail Individual Investors (RIIs) category subscribed 1.01 times. On day 1, Qualified Institutional Buyers (QIBs) were hesitant, with a subscription of 0.37 times. This issue also had an employee quota, which was subscribed 1.65 times, reflecting employees' confidence in the management.

Symbiotec Pharmalab raised ₹526 crores from 34 anchor investors by allocating 53.25 lakh equity shares at ₹988 per share. The anchor book included investors like Citigroup Global Markets, BNP Paribas, Susquehanna Pacific, Singularity AMC (backed by Madhusudan Kela), and TIMF Holdings.

GMP and investor sentiment on Day 1

Symbiotec Pharmalab's Grey Market Premium (GMP) was at ₹388 at the end of Day 1. At the upper price band of ₹988, this suggests a tentative listing price of ₹1,376, delivering a potential listing gain of 39.27%.

Investor sentiment is highly optimistic about the Symbiotec Pharmalab IPO, based on its position as the global leader in certain API products, its financial performance track record, and strong institutional anchor book backing.

However, market participants are also weighing its heavy reliance on corticosteroid and steroidal-hormone segments, along with the pharmaceutical industry’s high regulatory risks. Therefore, investors will be watching its subscription momentum and GMP numbers closely before its subscription window closes on August 27, 2026.